BMO Capital Starts Ambit Biosciences (AMBI) at Outperform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. SBUX

Go back to BMO Capital Starts Ambit Biosciences (AMBI) at Outperform

Leerink Swann Starts Ambit Biosciences (AMBI) at Outperform

June 10, 2013 7:51 AM EDT

Leerink Swann initiated coverage on Ambit Biosciences (NASDAQ: AMBI) with an Outperform rating and a price target of $14.00.

Analyst Howard Liang said, "In an area where chemotherapy remains as the standard of care with limited breakthrough, we see AMBI's quizartinib as the best-in-class FLT3... More

Citi Starts Ambit Biosciences (AMBI) at Buy

June 10, 2013 7:08 AM EDT

Citi initiates coverage on Ambit Biosciences (NASDAQ: AMBI) with a Buy. PT $13.00.

For an analyst ratings summary and ratings history on Ambit Biosciences click here. For more ratings news on Ambit Biosciences click here.

Shares of Ambit Biosciences closed at $7.79 yesterday, with a 52 week range of $6.22-$8.24.... More